TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Prescribed BOTOX® for the prophylaxis of headaches.~Exclusion Criteria:~* Received treatment with any botulinum toxin Type A serotype in the last 26 weeks~* Current participation in Allergan's Botox Chronic Migraine Post-Authorisation Safety Study (protocol 191622-110).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BOTOX® (Type: None): BOTOX® (botulinum toxin Type A) administered according to physician prescription for the treatment of chronic migraine; all treatment decisions lie with the physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronological age (CA) between 3 and 10 for girls~* Chronological age between 3 and 12 for boys~* Height for CA below - 2 SD~* Birth length for CA below -2SD~Exclusion Criteria:~* Endocrine disease except well-substituted hypothyroidism~* Sever chronic disease~* Skeletal dysplasia~* Known chromosomal aberration~* Ongoing treatment with steroids~* Known intrauterine infection

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Genotonorm A (Type: ACTIVE_COMPARATOR): Continuous 0.7 IU/kg/week or 0.03 mg/kg/day
- Genotonorm B (Type: ACTIVE_COMPARATOR): Continuous, 1.4 IU/kg/week or 0.06 mg/kg/day
- Genotonorm C (Type: ACTIVE_COMPARATOR): Intermittent, 1.4 IU/kg/week or 0.06 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Low-dose Primaquine Efficacy and Safety.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 1 to 10 years~* Weight ≥ 10 kg~* Body temperature ≥ 37.5°C or history of fever in the last 24 hours~* Microscopy confirmed P. falciparum mono-infection~* Parasitemia level of 2000 - 200000/µL~* Ability to swallow oral medication~* Ability and willingness to abide by the study protocol and the stipulated follow up visits~* Written proxy informed consent from a parent/guardian.~Exclusion Criteria:~* Evidence of severe malaria or danger signs~* Known allergy to trial medicines~* Reported antimalarial intake ≤ 2 weeks~* Hemoglobin \< 5 g/dL~* Blood transfusion within last 90 days~* Febrile condition other than malaria~* Known underlying chronic or severe disease

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntary participation in the study with signature on Informed Consent Form (ICF) prior to specific protocol procedures~* Patients of any race~* On outpatient treatment~* History of frequent symptom crises related to GERD within the last 3 months (at least a frequency of twice a week, for about four to eight weeks)~* Diagnosis of erosive esophagitis (grade A to D, according to Los Angeles Classification)~* In good health condition, except GERD symptoms~* Able to follow the protocol directions and to complete daily the questionnaire ReQuest™ throughout the study~Exclusion Criteria:~* Gastrointestinal disorder, even when related to chlorhydropeptic disorders: Barret's esophagus, peptic ulcer, Zollinger-Ellison syndrome and pyloric stenosis~* Previous history of surgery to reduce acid secretion, or other upper gastrointestinal tract surgeries (excepting polypectomy and cholecystectomy)~* At initial endoscopy presenting complicated disorders due to erosive esophagitis: obstructive esophageal stenoses, Schatzki ring, esophageal diverticulum, esophageal varices, achalasia and hiatal hernia~* Pregnant women or during nursing period~* Proton Pump Inhibitors (PPIs) within the last 10 days prior to start of the study~* Triple therapy based on PPIs to eradicate H. pylori within the last 28 days prior to start of the study~* H2-blockers, sucralfate and prokinetics within the last 7 days prior to start of the study~* Systemic glucocorticoids and/or nonsteroidal anti-inflammatory drugs (including COX-2 inhibitors) for more than 3 consecutive days a week, within the last 28 days prior to start of study, with exception of regular intake of acetyl salicylic acid in dosages of up to 163 mg/day.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Magnesium Pantoprazole (Type: ACTIVE_COMPARATOR): None
- Magnesium Esomeprazole (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Losartan on Insulin Resistance in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* chronic stable heart failure~Exclusion Criteria:~* renal dysfunction or under treatment with antidiabetic agents

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with T1D for at least 6 months at Screening.~* current usage of daily insulin treatment.~Exclusion Criteria:~* pregnant or nursing~* renal insufficiency~* hepatic synthetic insufficiency~* aspartate or alanine aminotransferase \> 3 times the upper limit of normal~* hematocrit less than or equal to 30%~* use of \> 2.0 U/kg total insulin dose per day~* inadequate venous access~* current seizure disorder~* history of pheochromocytoma or disorder with increased risk of pheochromocytoma~* history of insulinoma~* history of glycogen storage disease.~* active use of alcohol or drugs of abuse~* administration of glucagon within 14 days of the first treatment visit~* participation in other studies involving an investigational drug or device within 30 days

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- G-Pen (glucagon injection) 0.5 mg (Type: EXPERIMENTAL): A single 0.5 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
- G-Pen (glucagon injection) 1.0 mg (Type: EXPERIMENTAL): A single 1.0 mg subcutaneous (SC) injection of G-Pen (glucagon injection)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of Quizartinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory AML~* AML for which no standard treatment is available~* ECOG Performance Status (PS) of 0 to 2~Exclusion Criteria:~* Acute Promyelocytic Leukemia~* chronic myelogenous leukemia in blast phase (BCR-ABL fusion gene positive)~* History of other malignancies within 3 years prior to enrollment, except curatively treated in-situ carcinoma, AML, or MDS.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AC220 (Type: EXPERIMENTAL): This study will follow a mCRM (modified continual reassessment method) + EWOC (Escalation with Overdose Control) design.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose hCG in the Late Follicular Phase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \< 36 years on day of randomisation~* FSH \< 12 in the early follicular phase~* Normal ultrasound scan~* BMI between 18 and 29 (both inclusive)~* Randomisation at outpatient clinic~Exclusion Criteria:~* Endometriosis ≥ grade 3~* PCO syndrome~* Poor responder~* Endocrine or metabolic abnormalities

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins.
- B (Type: EXPERIMENTAL): Patients are undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) of 18.5 to 40 kg/m2~* On a stable maximum daily dose of a statin, defined as atorvastatin 80 mg or rosuvastatin 40 mg for a minimum of 45 days prior to Day 1.~* Lipids meet the following criteria twice during screening period:~* Fasting LDL C = or \> 80 mg/dL;~* Fasting TG \< 400 mg/dL.~Exclusion Criteria:~* History of a cardiovascular or cerebrovascular event or procedure (eg, MI, stroke, TIA, angioplasty) during the past year.~* Poorly controlled type 1 or type 2 diabetes mellitus.~* Poorly controlled hypertension.~* Fasting triglycerides \> 400 mg/dL~* 12 lead ECG demonstrating QTcFF \>455 msec at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: PLACEBO_COMPARATOR): None
- Treatment B (Type: EXPERIMENTAL): None
- Treatment C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is in good health (any underlying chronic illness must be documented to be in stable condition)~* Has documented proof of receipt of 23-valent pneumococcal polysaccharide vaccine ≥1 year prior to study entry~* Is a male or postmenopausal female~Exclusion Criteria:~* Has received prior administration of any pneumococcal vaccine other than 23-valent pneumococcal polysaccharide vaccine~* Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease~* Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine~* Is known or suspected impairment of immune function~* Has received systemic corticosteroids for \>=14 consecutive days and has not completed treatment \<=30 days prior to study entry, or received systemic corticosteroids exceeding physiologic replacement doses within 14 days prior to study vaccination~* Has a coagulation disorder contraindicating intramuscular vaccination~* Receives immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation, or autoimmune disease~* Has received a blood transfusion or blood products, including immunoglobulins within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion~* Has participated in another clinical study of an investigational product within 2 months before the beginning of or any time during the duration of the current clinical study~* Is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of V114 on Day 1.
- Prevnar 13™ (Type: ACTIVE_COMPARATOR): Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Either has medically-confirmed diagnosis of chronic constipation (per Rome III), or meets the diagnosis as confirmed using the Rome III constipation module questionnaire during the Screening period.~* Is male or female, 18 or older years of age~* Should be on stable dose of fiber supplement or a concomitant medication for the indication of lowering blood pressure~Exclusion Criteria:~* Has any gastrointestinal (GI) condition, other than constipation, affecting GI motility or defecation~* Is unable to eat or drink, take oral medications, or to hold down oral medications due to vomiting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lubiprostone Capsule (Type: ACTIVE_COMPARATOR): Lubiprostone 24 mcg capsule twice daily (BID) for 7 days.
- Lubiprostone Sprinkle (Type: EXPERIMENTAL): Lubiprostone 24 mcg sprinkle BID for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching to lubiprostone (sprinkle/capsule) BID for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* 40-75 years of age~* Clinical diagnosis of moderate to severe COPD~* Current/ex-smokers with at least 10 pack-year smoking history~* Post-bronchodilator FEV1 ≥ 30% and ≤ 70% predicted normal values~* Post-bronchodilator FEV1/FVC ratio of ≤ 0.70~* Post-bronchodilator improvement in FEV1 ≥ 12% and ≤ 30%, and a minimum of 100 mL~* Willing and able to remain at the study site for at least 24 hours at each study visit~* Signed written informed consent~Exclusion Criteria:~* Current evidence or recent history of any clinically significant and unstable disease or abnormality (e.g., myocardial infarction, cardiac failure, uncontrolled hypertension, life-threatening arrhythmias, uncontrolled diabetes)~* Primary diagnosis of asthma~* History of malignancy within the past 5 years~* History of COPD exacerbation within 6 weeks of Screening~* Daily oxygen therapy \> 10 hours per day~* Systemic steroids use within 6 weeks of Screening~* Respiratory tract infection within 6 weeks of Screening~* History of tuberculosis, bronchiectasis~* History of urinary retention or bladder neck obstruction type symptoms~* History of glaucoma~* Prolonged QTc interval (\>460msec) or history of long QT syndrome~* Recent history of alcohol or drug abuse~* Females who are pregnant or breastfeeding, or if of child-bearing potential unwilling to practice acceptable birth control methods~* History of hypersensitivity or intolerance to aerosol medications~* Participation in another investigational drug study within 30 days of Screening

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EP-101 via nebulizer (eFlow®) 25 ug (Type: EXPERIMENTAL): EP-101 via nebulizer (eFlow®)
- Tiotropium bromide via (Spiriva® Handihaler®) (Type: ACTIVE_COMPARATOR): Tiotropium bromide via (Spiriva® Handihaler®)
- Ipratropium bromide Inhalation Solution (Type: ACTIVE_COMPARATOR): Ipratropium bromide Inhalation Solution via Handihaler® DPI
- Placebo EP-101 (Type: PLACEBO_COMPARATOR): Placebo
- EP-101 via nebulizer (eFlow®) 50 ug (Type: EXPERIMENTAL): EP-101 via nebulizer (eFlow®)
- EP-101 via nebulizer (eFlow®) 100 ug (Type: EXPERIMENTAL): EP-101 via nebulizer (eFlow®)
- EP-101 via nebulizer (eFlow®) 200 ug (Type: EXPERIMENTAL): EP-101 via nebulizer (eFlow®)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Evidence of metastatic or surgically unresectable transitional cell carcinoma of the urothelium involving the bladder,urethra,ureter or renal pelvis~* Measurable disease by CT or MRI~* Progression or recurrence after treatment~* i) With at least 1 platinum-containing chemotherapy regimen for metastatic or surgically unresectable locally advanced urothelial cancer, or~* ii) Within 12 months of peri-operative (neo-adjuvant or adjuvant) treatment with a platinum agent in the setting of cystectomy for localized muscle-invasive urothelial cancer~* Subject that have received more than 2 prior lines of chemotherapy must not have liver metastases~* Tumor tissues (archived or new biopsy) must be provided for biomarker analysis~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1~Exclusion Criteria:~* Subjects with active cancer that has spread to the central nervous system~* Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured~* Subject with active, known or suspected autoimmune disease~* Subjects with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 day of study drug administration~* Prior treatment with an anti-PD-1,anti-PD-L1,anti-PD-L2,anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, anti-CD137 or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways~Exclusion laboratory criteria:~* Positive test for hepatitis B virus surface antigen (HBV s Ag) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection~* Known history of testing positive for human Immunodeficiency virus (HIV) or known acquired Immunodeficiency syndrome (AIDS)~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab (Type: EXPERIMENTAL): Nivolumab intravenous infusion as specified

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete